E-LIB Suche - Ergebnisse für: Casasnovas, O.

1

CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HE..:

Loyaux, R. ; Sako, N. ; Quang, V. Tran...
Hematological Oncology. 41 (2023) S2 - p. 108-110 , 2023

Link: https://doi.org/10.1002/..

2

Long term follow‐up of untreated/relapsing MCL patients wit..:

Le Gouill, S. ; Morschhauser, F. ; Chiron, D....
Hematological Oncology. 41 (2023) S2 - p. 478-479 , 2023

Link: https://doi.org/10.1002/..

3

Distinct molecular determinants of treatment‐failure in eld..:

Rossi, C. ; Boegeholz, J. L. ; Alig, S. K....
Hematological Oncology. 41 (2023) S2 - p. 321-322 , 2023

Link: https://doi.org/10.1002/..

4

Transfusion needs after CD19 CAR T‐cells for large B‐cell l..:

Vic, S. ; Thibert, J. ; Bachy, E....
Hematological Oncology. 41 (2023) S2 - p. 534-536 , 2023

Link: https://doi.org/10.1002/..

5

RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRA..:

Thieblemont, C. ; Chartier, L. ; Vercellino, L....
Hematological Oncology. 41 (2023) S2 - p. 91-91 , 2023

Link: https://doi.org/10.1002/..

6

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC n..:

Dufour, J. ; Choquet, S. ; Hoang-Xuan, K....
Annals of Hematology. 102 (2023) 5 - p. 1159-1169 , 2023

Link: https://doi.org/10.1007/..

7

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG ..:

Sarkozy, C. ; Thieblemont, C. ; Oberic, L....
Hematological Oncology. 41 (2023) S2 - p. 151-152 , 2023

Link: https://doi.org/10.1002/..

8

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:

Houot, R. ; Bachy, E. ; Cartron, G....
Hematological Oncology. 41 (2023) S2 - p. 147-148 , 2023

Link: https://doi.org/10.1002/..

9

Prognostic Value of Lymphopenia and Total Metabolic Tumor V..:

Willaume, A. ; Chartier, L. ; Ricci, R....
Hematological Oncology. 41 (2023) S2 - p. 346-347 , 2023

Link: https://doi.org/10.1002/..

10

Cell‐free DNA sequencing allows the identification of the m..:

Sako, N. ; Delfau, M. ; Bachy, E....
Hematological Oncology. 41 (2023) S2 - p. 338-339 , 2023

Link: https://doi.org/10.1002/..

11

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE I..:

Thieblemont, C. ; Lamy, T. ; Tani, M....
Hematological Oncology. 41 (2023) S2 - p. 104-106 , 2023

Link: https://doi.org/10.1002/..

12

P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NER..:

Renaud, L. ; Stéphan, P. ; durand, S....
HemaSphere. 6 (2022) - p. 1103-1104 , 2022

Link: https://doi.org/10.1097/..

13

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT ..:

Cartron, G. ; Bachy, E. ; Tilly, H....
HemaSphere. 6 (2022) - p. 1023-1024 , 2022

Link: https://doi.org/10.1097/..

14

HIGH ADIPOSE TISSUE DENSITY IS A NEGATIVE PROGNOSTIC FACTOR..:

Deux, J.‐F. ; Meignan, M. ; Chartier, L....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAP..:

Maerevoet, M. ; Casasnovas, O. ; Cartron, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..